Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

References for PMC Articles for PubMed (Select 23805138)

1.

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

Liao W, Lin JX, Leonard WJ.

Immunity. 2013 Jan 24;38(1):13-25. doi: 10.1016/j.immuni.2013.01.004. Review.

2.

The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens.

Gray DH, Kupresanin F, Berzins SP, Herold MJ, O'Reilly LA, Bouillet P, Strasser A.

Immunity. 2012 Sep 21;37(3):451-62. doi: 10.1016/j.immuni.2012.05.030. Epub 2012 Sep 6.

3.

Defective cell death signalling along the Bcl-2 regulated apoptosis pathway compromises Treg cell development and limits their functionality in mice.

Tischner D, Gaggl I, Peschel I, Kaufmann M, Tuzlak S, Drach M, Thuille N, Villunger A, Jan Wiegers G.

J Autoimmun. 2012 Feb;38(1):59-69. doi: 10.1016/j.jaut.2011.12.008. Epub 2012 Jan 17.

4.
5.

The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function.

Yang K, Neale G, Green DR, He W, Chi H.

Nat Immunol. 2011 Jul 17;12(9):888-97. doi: 10.1038/ni.2068.

6.

Defects in the Bcl-2-regulated apoptotic pathway lead to preferential increase of CD25 low Foxp3+ anergic CD4+ T cells.

Zhan Y, Zhang Y, Gray D, Carrington EM, Bouillet P, Ko HJ, O'Reilly L, Wicks IP, Strasser A, Lew AM.

J Immunol. 2011 Aug 15;187(4):1566-77. doi: 10.4049/jimmunol.1100027. Epub 2011 Jul 8.

7.

Bcl-2 allows effector and memory CD8+ T cells to tolerate higher expression of Bim.

Kurtulus S, Tripathi P, Moreno-Fernandez ME, Sholl A, Katz JD, Grimes HL, Hildeman DA.

J Immunol. 2011 May 15;186(10):5729-37. doi: 10.4049/jimmunol.1100102. Epub 2011 Mar 30.

8.

A major role for Bim in regulatory T cell homeostasis.

Chougnet CA, Tripathi P, Lages CS, Raynor J, Sholl A, Fink P, Plas DR, Hildeman DA.

J Immunol. 2011 Jan 1;186(1):156-63. doi: 10.4049/jimmunol.1001505. Epub 2010 Nov 22.

9.

Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells.

Barron L, Dooms H, Hoyer KK, Kuswanto W, Hofmann J, O'Gorman WE, Abbas AK.

J Immunol. 2010 Dec 1;185(11):6426-30. doi: 10.4049/jimmunol.0903940. Epub 2010 Oct 29.

10.

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.

Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA, Hernandez JM, Roman-Gomez J, Prosper F, Martinez-Climent JA.

Blood. 2010 Oct 7;116(14):2531-42. doi: 10.1182/blood-2010-02-268003. Epub 2010 Jun 22.

11.

IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.

De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K.

Blood. 2010 Mar 25;115(12):2430-40. doi: 10.1182/blood-2009-07-232801. Epub 2010 Jan 19.

12.

Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging.

Agius E, Lacy KE, Vukmanovic-Stejic M, Jagger AL, Papageorgiou AP, Hall S, Reed JR, Curnow SJ, Fuentes-Duculan J, Buckley CD, Salmon M, Taams LS, Krueger J, Greenwood J, Klein N, Rustin MH, Akbar AN.

J Exp Med. 2009 Aug 31;206(9):1929-40. doi: 10.1084/jem.20090896. Epub 2009 Aug 10.

13.

Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.

Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ.

PLoS Pathog. 2009 Jun;5(6):e1000492. doi: 10.1371/journal.ppat.1000492. Epub 2009 Jun 26.

14.

T-cell immunosenescence: lessons learned from mouse models of aging.

Maue AC, Yager EJ, Swain SL, Woodland DL, Blackman MA, Haynes L.

Trends Immunol. 2009 Jul;30(7):301-5. doi: 10.1016/j.it.2009.04.007. Epub 2009 Jun 21. Review.

15.

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.

San José-Eneriz E, Agirre X, Jiménez-Velasco A, Cordeu L, Martín V, Arqueros V, Gárate L, Fresquet V, Cervantes F, Martínez-Climent JA, Heiniger A, Torres A, Prósper F, Roman-Gomez J.

Eur J Cancer. 2009 Jul;45(10):1877-89. doi: 10.1016/j.ejca.2009.04.005. Epub 2009 May 4.

PMID:
19403302
16.

Tuning microenvironments: induction of regulatory T cells by dendritic cells.

Belkaid Y, Oldenhove G.

Immunity. 2008 Sep 19;29(3):362-71. doi: 10.1016/j.immuni.2008.08.005. Review.

17.

IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development.

Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA.

J Immunol. 2008 Sep 1;181(5):3285-90.

18.

Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation.

Lages CS, Suffia I, Velilla PA, Huang B, Warshaw G, Hildeman DA, Belkaid Y, Chougnet C.

J Immunol. 2008 Aug 1;181(3):1835-48.

19.

Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation.

Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10113-8. doi: 10.1073/pnas.0711106105. Epub 2008 Jul 17.

20.

A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells.

Bayer AL, Lee JY, de la Barrera A, Surh CD, Malek TR.

J Immunol. 2008 Jul 1;181(1):225-34.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk